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A phase I/II trial was designed to evaluate the safety and efﬁcacy of adding bortezomib to standard BEAM
(BCNU, etoposide, cytarabine, melphalan) and autologous hematopoietic stem cell transplantation (ASCT).
Eligible patients had relapsed/refractory indolent or transformed non-Hodgkin lymphoma or mantle cell
lymphoma (MCL) that was relapsed/refractory or in ﬁrst partial (PR) or complete remission (CR). Patients
received bortezomib on days 11, 8, 5, and 2 before ASCT. Phase I had 4 dose cohorts (.8, 1, 1.3, and
1.5 mg/m2) and 3 patients were accrued to each. Any nonhematological ASCT-related toxicity >2 on the
Bearman scale occurring between day 11 and engraftment deﬁned the maximum tolerated dose (MTD).
After the MTD has been reached, another 20 patients were enrolled at this dose to determine a preliminary
overall response rate (ORR). Patients who were in CR or PR at day þ100 were considered responders. The
study enrolled 42 patients through August 14, 2009. The median age was 58 (range, 34 to 73) years, with 33
males and 9 females. The most common diagnoses were MCL (23 patients) and follicular lymphoma (7 pa-
tients). The median number of prior therapies was 1 (range, 0 to 6). The median follow-up was 4.88 (range,
1.07 to 6.98) years. Thirteen patients were treated in phase I and 29 patients were treated in phase II. The MTD
was initially determined to be 1.5 mg/m2 but it was later decreased to 1 mg/m2 because of excessive
gastrointestinal toxicity and peripheral neuropathy. The ORR was 95% at 100 days and 87% at 1 year. For all 38
evaluable patients at 1 year, responses were CR 84%, PR 1%, and progressive disease 13%. Progression-free
survival (PFS) was 83% (95% CI, 68% to 92%) at 1 year, and 32% (15% to 51%) at 5 years. Overall survival
(OS) was 91% (95% CI, 79% to 96%) at 1 year and 67% (50% to 79%) at 5 years. The most common National
Cancer Institute grade 3 toxicities were neutropenic fever (59%), anorexia (21%), peripheral neuropathy (19%),
orthostatic hypotension/vasovagal syncope (16%), and 1 patient failed to engraft. Compared with 26 MCL in
CR1 historic controls treated with BEAM and ASCT, PFS was 85% and 43% for the BEAM group versus 87% and
57% for those who received bortezomib in addition to standard BEAM (V-BEAM) at 1 and 5 years, respectively
(log-rank P ¼ .37). OS was 88% and 50% for the BEAM group versus 96% and 72% for V-BEAM at 1 and 5 years,
respectively (log-rank P ¼ .78). In conclusion, V-BEAM and ASCT is feasible. The toxicities were manageable
and we did not observe any treatment-related mortalities; however, we did observe an excess of autonomic
dysfunction and ileus, which is concerning for overlapping toxicity with BEAM conditioning. Determining
relative efﬁcacy of V-BEAM compared to BEAM would require a randomized trial.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Patients with relapsed indolent lymphomas and high-risk
mantle cell lymphoma (MCL), have high complete remission
(CR) rates after high-dose therapy (HDT) and autologous
stem cell transplantation (ASCT), yet there are still a signiﬁ-
cant number of patients who relapse after this procedure.edgments on page 541.
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14.01.004Follicular lymphoma (FL) accounts for approximately 25% of
all newly diagnosed cases of non-Hodgkin lymphoma (NHL).
The disease course of indolent lymphomas, including FL, is
generally one of remissions and exacerbations followed
frequently by resistance and transformation to a more
aggressive NHL histology. One randomized controlled trial
[1] and several retrospective analyses [2-4] demonstrated
improved progression-free survival (PFS) when ASCT was
used as a consolidation after salvage therapy for patients
with FL in ﬁrst relapse. In the European CUP (chemotherapy,
unpurged marrow, purged marrow) trial, ASCT improved 2-
year PFS from 26% to 58%, establishing ASCT as the stan-
dard of care of relapsed FL patients [1]. Patients who have
transformed from a FL to more aggressive NHLs are felt to
have a poor prognosis with standard therapies [5]. However,
if patients have at least a partial response (PR) to salvageTransplantation.
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found to have a prognosis similar to patients receiving a
similar transplantation for FL [6,7].
MCL is an aggressive form of NHL and it accounts for 5% to
6% of all newNHL diagnoses [8]. With standard therapies, the
prognosis of MCL is poor, with an average PFS of 8 to
20 months [9,10]. With the introduction of rituximab and the
use of upfront intensiﬁed treatment regimens, like hyper-
CVAD, (cyclophosphamide, vincristine, doxorubicin, dexa-
methasone, alternating with high dose methotrexate and
cytarabine) and/or ASCT in ﬁrst CR, 5-year PFS of 50% to 60%
has become achievable [11-15]. T cell prolymphocytic leu-
kemia, when treated with standard therapy, has a poor
prognosis. However, studies using ASCT have produced some
early promising results [16].
Various HDT regimens were used before ASCT in patients
with NHL, yet little is known regarding the comparative
toxicity and efﬁcacy of these regimens, as no randomized
trials were performed. The BEAM (carmustine, etoposide,
cytarabine, and melphalan) regimen is one of the most
popular HDT regimens employed before ASCT for lym-
phomas since its introduction in the 1980s [17]. Retrospec-
tive data suggested lower toxicity and improved outcomes
when compared with older carmustine-based regimens
[18,19]. The rate of progression after HDT and ASCT remains
around 40% for relapsed or transformed indolent NHLs and
high-risk MCL [1,7,12,15], and novel treatments to improve
outcomes of these patients are needed. Bortezomib (Velcade,
Millennium Pharmaceuticals Inc., Cambridge, MA) is a novel,
small molecule proteasome inhibitor approved in the United
States for treatment of multiple myeloma. The antineoplastic
effect of bortezomib likely involves several distinct mecha-
nisms, including inhibition of cell growth and survival
pathways, induction of apoptosis, and inhibition of expres-
sion of genes that control cellular adhesion, migration, and
angiogenesis. Nuclear factor-kB is constitutively activated in
MCL [20], FL [21], andmarginal zone lymphoma [22], and it is
a major player in mediating resistance to chemotherapeutic
agents. Inhibition of the proteasome in MCL led to rapid
down-regulation of nuclear factor-kB and apoptosis of MCL
cells [20]. Bortezomib has shown signiﬁcant single-agent
activity against relapsed/refractory indolent and mantle cell
lymphomas in multiple small single-institution trials [23-
25]. The landmark PINNACLE trial showed an overall
response rate (ORR) for single-agent bortezomib of 33% in
144 assessable patients with relapsed/refractory MCL, with
an average duration of response of 9.2 months [26].
It was hoped that the addition of bortezomib to standard
BEAM conditioning would improve the outcome of patients
with relapsed indolent NHL and MCL without excessive
toxicity. We designed a phase I/II study to evaluate the safety
and efﬁcacy of escalating doses of bortezomib added to
standard ﬁxed dose of BEAM regimen (V-BEAM) before ASCT
for relapsed indolent and high-risk MCL patients.
SUBJECTS AND METHODS
Eligibility Criteria
Inclusion criteria included age 19 years or older and persistent, relapsed,
or refractory indolent NHL including FL, composite lymphomas with 50%
of tumor showing follicular histology, transformed follicular, lympho-
plasmacytic, marginal zone lymphoma, small lymphocytic lymphoma
(including Tcell subtypes), MCL (MCLwere included only if theywere in ﬁrst
CR), or any peripheral T cell lymphoma that was relapsed, refractory, or in
ﬁrst CR or PR. We included heterogeneous group of patients with NHL in
whom HDT followed by ASCT is considered to be the standard of care and
who have a disease that has been historically associated with a high risk of
relapse after HDT and ASCT. Additional inclusion criteria were expectedsurvival duration of 6 months or more, Karnofsky performance status of 70%
or higher, liver functions <3 times upper limits of normal unless due to
disease, serum creatinine <2.5 mg/dL or calculated creatinine clearance
>50 mL/min, absolute neutrophil count >500 cells/mm3, and platelet count
>50 mm3. Patients older than 60 years or with clinical signs of heart disease
must have had an ejection fraction  45%. Patients with clinical signs of
pulmonary insufﬁciency must have had diffusion capacity of carbon mon-
oxide higher than 50% of predicted value. Patient must have been able to
collect more than 1.2  106/kg CD34þ cell for transplantation. All patients
signed a written informed consent. Male and female patients of reproduc-
tive potential were required to follow accepted birth control measures.
Exclusion criteria included human immunodeﬁciency virus seroposi-
tivity; active infection at the time of transplantation; myocardial infarction
within 6 months before enrollment; New York Hospital Association class III
or IV heart failure; uncontrolled angina; severe uncontrolled ventricular
arrhythmias; electrocardiographic evidence of acute ischemia or active
conduction system abnormalities; a serious disease or condition that, in the
opinion of the investigators, would compromise the patient’s ability to
participate in the study; pregnant or lactating females; or hypersensitivity to
bortezomib, boron, or mannitol.
Study Design and Preparatory Regimen
This was a single-institution phase I/II study where escalating doses of
bortezomib were given with standard dose of BEAM in the inpatient setting
as a conditioning regimen before ASCT. In Phase I of the study, bortezomib
was administered in 4 dose cohorts: .8 mg/m2, 1.0 mg/m2, 1.3 mg/m2, and
1.5mg/m2. Three patients were accrued in each dose cohort with enrollment
starting at dose cohort 1 (.8 mg/m2). Bortezomib was given on days 11,
8, 5, and 2. All study patients received BEAM conditioning per our
standard institution protocol: carmustine (BCNU) 300 mg/m2 on day 5,
etoposide 100 mg/m2 twice daily on days 5, 4, 3, and 2, cyatabine
100 mg/m2 twice daily on days 5, 4, 3, and 2, and melphalan 140 mg/
m2 on day 1 before infusion of autologous stem cells. The objective of
phase I was to determine the maximum tolerated dose (MTD) of bortezomib
in this setting. The MTD was deﬁned by observing any nonhematologic
transplantation-related toxicity higher than grade 2 on the Bearman scale
[27] occurring between day 11 (ﬁrst bortezomib infusion) and engraft-
ment. After the MTD was deﬁned, we enrolled another 20 patients to obtain
a preliminary estimate of ORR, progression-free survival, and overall sur-
vival (OS) using this regimen.
Supportive Care and Clinical Monitoring
Peripheral blood stem cells were collected per the discretion of the
treating physician. Once an adequate number of CD34þ cells/kg had been
collected (per standard institutional protocol) the patient started the pre-
parative regimen for transplantation. Filgrastimwas started at 5 mg/kg daily
at day þ7 after stem cell infusion, and patients received ﬂuconazole and
acyclovir prophylaxis until count recovery (per standard intuitional proto-
col). Packed RBCs and platelet transfusions were administered to maintain a
hemoglobin level >8 g/dL and a platelet count >10  109/L. Blood cultures
were drawn and patients were treated with broad-spectrum antibiotics
when fever developed, per standard clinical practices. Patients were eval-
uated daily by physical examination and laboratory studies from day -11
until hospital discharge and then were followed on an outpatient basis, as
clinically indicated. Patients were restaged at day þ100, and again 1 year
after ASCT with imaging studies (computed tomography, positron emission
tomographyecomputed tomography, or magnetic resonance imaging scans
as clinically indicated). Restaging bone marrow biopsies were performed
only in patients who had a prior history of disease involving the bone
marrow. Responses were evaluated according to those reported elsewhere
by Cheson et al. [28]. All toxicities were deﬁned by use of the National
Cancer Institute’s Common Terminology Criteria for Adverse Events Version
3.0 (2003). Patient who were in CR or PR at day þ100 were considered
responders.
Statistical Analysis
The primary objective of the study was to evaluate the toxicity and
determine the MTD of bortezomib when added to a standard BEAM condi-
tioning regimen followed by ASCT. The secondary objective of the study was
to obtain a preliminary estimate of the ORR, PFS, and OS with this regimen.
The phase I section of the study followed a standard 3 þ 3 design: 3 patients
were enrolled at the initial dose level. If 2 of the 3 patients in the initial
cohort had a dose-limiting toxicity (DLT), 3 additional patients were enrolled
to that dose level. If 3 of 6 patients experienced a DLT, as deﬁned as grade>2
on the Bearman scale, no further dose escalation occurred. If 2 of 3 patients
in dose cohorts 2, 3, or 4 had a DLT, 3 additional patients were enrolled to
that dose cohort. If 2 of 6 patients experienced a DLT, no further dose
escalation occurred. TheMTD is deﬁned to be the dose cohort belowwhich 3
Table 2
Adverse Events Reported in  20% of Patients (N ¼ 42) Plus Incidences of





Neutropenic fever 29 (59%) 29 (59%) 29 (59%)
Mucositis/stomatitis 29 (59%) 0 29 (59%)
Diarrhea 23 (54%) 2 (4%) 23 (54%)
Anorexia 15 (35%) 9 (21%) 15 (35%)
Peripheral neuropathy 14 (33%) 8 (19%) 13 (30%)
Rash 12 (28%) 1 (2%) 10 (23%)
Constipation 11 (26%) 1 (2%) 10 (23%)
Vasovagal syncope/
orthostatic hypotension
10 (23%) 7 (16%) 9 (21%)
Nausea and vomiting 5 (11%) 1 (2%) 5 (11%)
Hypokalemia 5 (11%) 5 (11%) 5 (11%)
Hypoxia 5 (11%) 2 (4%) 5 (11%)
Ileus 4 (9%) 4 (9%) 4 (9%)
Renal insufﬁciency 4 (9%) 1 (2%) 4 (9%)
Data presented are n (%).
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were not observed at any dose cohort. To reﬁne the estimate of ORR, 20
additional patients were accrued at the MTD. If 3 patients were accrued at
the MTD in the phase I portion, accruing 20 additional patients reduced the
maximum width of the 95% conﬁdence interval for the response rate from
.58 to .21. If 6 patients are accrued at theMTD in the phase I portion, accruing
20 additional patients reduced the maximum width of the 95% conﬁdence
interval for the response rate from .41 to .20. Patients enrolled at the MTD in
the phase I portion were included in the ﬁnal estimate of response rate. OS
and PFS were estimated according to Kaplan-Meier method. The log-rank
test was used to assess the signiﬁcance of differences for each prognostic
factor in the univariate analysis. The Cox proportional hazards regression
model and the logistic regression models were used to assess how patients’
characteristics predict PFS and OS. Analyses were performed using SAS
software, version 9.1 (SAS Institute, Cary, NC). Two-sided tests were used in




In total, 42 patients were enrolled (13 patients in phase I
and 29 patients in phase II) until August 14, 2009. All
completed the treatment and proceeded to transplantation.
Baseline characteristics are presented in Table 1. Themedian
age of subjects was 58 years and themedian number of prior
therapies was 1. Fifty-ﬁve percent of these patients had MCL
and 62% of the patients underwent transplantation in CR1.
The median duration of follow-up was 4.88 (1.07 to 6.98)
years. All patients with MCL received upfront therapy with
Rituximab-HyperCVAD regimen and most subjects with
other subtypes of lymphomas received cyclophosphamide,
vincristine, doxorubicin, prednisone (CHOP)/cyclophos-
phamide, vincristine, prednisone (CVP) or R-CHOP/CVP.
Cumulative exposure to vincristine was comparable across
subjects. Only 2 of the subjects received bortezomib with
salvage chemotherapy pretransplantation. None of the
study subjects had more than grade 1 neuropathy upon
enrollment.
Safety
All 42 patients were evaluable for safety. As expected,
all patients experienced at least 1 adverse event (AE), 39
(93%) experienced at least 1 grade 3 or higher AE, and 34
(81%) were related to the conditioning regimen. The most
common grade 3 AEs were neutropenic fever (59%),Table 1
Patient Characteristics
Parameter Value (N ¼ 42)
Median age (range), yr 58 (34-73)
Male/female 33/9
Histology 23
 Mantle cell lymphoma 6
 Nodular mantle cell lymphoma 6
 Follicular lymphoma 1
 Diffuse large B cell//transformed FL-3 1
 Marginal zone lymphoma 1
 B lymphoplasmacytic lymphoma 1
 Small lymphocytic lymphoma 1
 T Prolymphocytic leukemia 1
 Anaplastic large cell lymphoma 1
Prior courses of systemic therapy, median (range) 1 (1-6)
Disease stage at transplantation (%)
 CR1 26 (62%)
 CR3 1 (2%)
 Primary induction failure/chemosensitive disease 12 (29%)
 Relapsed 3 (7%)
Follow-up of survivors, median (range), mo 32 (12-55)
FL indicates follicular lymphoma; CR, complete remission.
Data presented are n (%) unless otherwise indicated.anorexia (21%), peripheral neuropathy (19%), and ortho-
static hypotension/vasovagal syncope (16%). Overall in-
cidences of AEs are reported in Table 2. Infectious
complications are reported separately in Table 3. The most
common infectious complications, in addition to neu-
tropenic fever, were bacteremias (26%) and clostridium
difﬁcile colitis (23%). The most common organisms causing
bacteremias were streptococcus viridans and coagulase-
negative staphylococcus.
The MTD was initially determined to be 1.5 mg/m2 but
was later decreased to 1 mg/m2 because of excessive gas-
trointestinal toxicity and peripheral neuropathy (in phase II
patients). Grade 3 ileus was observed in 9% of patients and 1
patient had perforation of the jejunum with necrosis; this
was possibly related to the treatment. The median time to
onset of neuropathy was 5 weeks (range, 2 to 24 weeks). Five
of 8 (62%) patients with grade 3 neuropathy required treat-
ment and 3 of 5 subjects were able to stop treatment of
neuropathy after 1 to 6 years. None of the orthostatic hy-
potension/vasovagal syncope episodes observed required
ﬂudrocortisone replacement or any other speciﬁc treatment
beyond administration of intravenous ﬂuids, and all resolved
before hospital discharge.
The breakdown of bortezomib dose given is shown in
Table 4. No treatment-related mortality was observed in the
study. All patients, except 1, had successfully engrafted with
mean time to absolute neutrophil count >500 cells/mm3 of
11 days (range, 9 to 15). Mean time to independence of RBC
transfusions was 10 days (range, 1 to 38) and 7 patients did
not need RBC transfusions. Mean time to independence of
platelet transfusions was 16 days (range, 7 to 36). Mean
number of days of granulocyte colony-stimulating factor
support was 6 (range, 2 to 28).Table 3
Infectious Events Reported and Severity
Event Any Grade Grade  3
Neutropenic fever 29 (59%) 29 (59%)
Clostridium difﬁcile colitis 10 (23%) 5 (11%)
Bacteremia 11 (26%) 10 (23%)
Cellulitis 3 (7%) 1 (2%)
Urinary tract infection 3 (7%) 2 (4%)
Herpes zoster 3 (7%) 0
Bacterial enteritis 1 (2%) 0
Upper respiratory infection 1 (2%) 0
Data presented are n (%).
Table 4
Breakdown of Bortezomib Dose Given during Phase I and Phase II
Bortezomib Dose No. of Patients
Phase I
 .8 mg 3
 1.0 mg 4
 1.3 mg 3
 1.5 mg 3
Phase II
 1.0 mg 6
 1.3 mg 12
 1.5 mg 11
Figure 2. Kaplan-Meier curves for phase II patients (n ¼ 29). (A) Shows
progression-free survival and (B) shows overall survival.
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All patients enrolled in the study progressed on at least 1
line of therapy, except for MCL patients who underwent
transplantation in CR1. The median duration of follow-up
was 4.88 (1.07 to 6.98) years. At day þ100 after ASCT, 40
patients were evaluable for response; 36 (86%) were in CR
and 2 (5%) were in PR with ORR of 95%. One patient had
stable disease (5%) and another patient had disease pro-
gression (PD) (5%). At 1 year after ASCT, 38 patients were
evaluable for response; 32 (84%) were in CR and 1 (3%) was in
PR with ORR of 87%. Five patients (13%) had PD. The PFS was
83% (95% conﬁdence intervals [CI], 68% to 92%) at 1 year and
32% (95% CI, 15% to 51%) at 5 years. The OS was 91% (95% CI,
79% to 96%) at 1 year and 67% (95% CI, 50% to 79%) at 5 years
(Figure 1). Phase II patients (n ¼ 29) were analyzed sepa-
rately and at day 100 after ASCT, 28 patients were evaluable
for response; 26 (90%) were in CR, 1 (3%) was in PR, and 1
(3%) had stable disease with ORR of 96%. At 1 year after ASCT,
27 phase II patients were evaluable for response: 22 (81%)
were in CR and 1 (4%) was in PR with ORR of 89%. Four pa-
tients (15%) had PD. The PFS was 83% (63% to 92%) at 1 yearFigure 1. Kaplan-Meier curves for all study patients (N ¼ 42). (A) Shows
progression-free survival and (B) shows overall survival.and 42% (15% to 67%) at 5 years. The OS was 96% (78% to 96%)
at 1 year and 74% (52% to 86%) at 5 years (Figure 2). In an
exploratory analysis, PFS and OS were not different between
patients based on histology: PFS and OS at 3 years were 72%
and 82% for MCL versus 75% and 100% for FL versus 67% and
100% for other histologies (log-rank P ¼ .95 and P ¼ .58,
respectively). Therewas a trend towards better PFS at 3 years
for patients who underwent transplantation in CR1 (85%)
versus others (50%), yet that was not statistically signiﬁcant
(log-rank P ¼ .15). OS at 3 years based on disease status at
transplantation was not different, though; 90% for patients
who underwent transplantation in CR1 versus 86% for others
(log-rank P ¼ .94).
Comparison with Historic MCL Patients
In an exploratory analysis, we compared 23 patients with
MCL accrued to this study (V-BEAM group) to 26 historicMCL
patients (BEAM group) who received standard BEAM fol-
lowed by ASCT at our institution between the years of 2006
and 2009 to determine if the addition of bortezomib had a
dramatic inﬂuence on outcomes in patients with MCL. There
was no signiﬁcant difference in baseline characteristics be-
tween study and historic patients, as summarized in Table 5.
PFS (Figure 3A) was 85% and 43% for the BEAM group versus
87% and 57% for V-BEAM at 1 and 5 years, respectively (log-
rank P¼ .37). OS at 1 and 5 years (Figure 3B) was 88% and 50%
for the BEAM group versus 96% and 72% for V-BEAM,
respectively (log-rank P ¼ .74).
DISCUSSION
Recent data demonstrated improved survival of patients
with MCL over the last 2 years because of adoption of HDT
Table 5
Comparison between Patient Characteristics of Study Patients and Historic
Patients with Mantle Cell Lymphoma
Variable BEAM V-BEAM P Value
Number 26 23
Age, median (range), yr 57 (36-74) 58 (36-71) .87
Male sex 23 (88) 17 (74) .19
Ann Arbor staging at
diagnosis
.90
I 1 (4) 2 (9)
II 1 (4) 1 (4)
III 3 (12) 3 (13)
IV 21 (80) 17 (74)
Presence of B symptoms 5 (19) 7 (30) .46
Elevated serum LDH 9 (35) 5 (22) .37
Time from diagnosis to
treatment, median
(range), mo
6 (4-62) 6 (4-9) .42
Interval from diagnosis to
treatment
.17
 1 year 24 (92) 23 (100)
>1 year 2 (8) d
No. of prior treatments .55
1 21 (81) 20 (87)
2 5 (19) 3 (13)
Follow-up time of survivors,
median (range), yr
1.97 (.99-4.89) 2.79 (1.07-4.56) .06
LDH indicates lactate dehydrogenase.
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improved CR rates; however; it did not improve PFS or OS in
patients when added to standard CHOP chemotherapy [9].
Earlier retrospective single-institution data have shown
improved outcomes with HDT followed by ASCT [29]. TheFigure 3. Comparison between study MCL patients (V-BEAM) versus historic
MCL patients (BEAM). (A) Shows progression-free survival and (B) shows
overall survival.European Mantle Cell Lymphoma Network designed a pro-
spective randomized trial comparing consolidation with
myeloablative radiochemotherapy followed by ASCT versus
interferon maintenance in patients with MCL who attained a
CR after CHOP induction. Of the 122 evaluable patients, the
median PFS was better for the transplantation arm (39
months versus 17 months) and an OS beneﬁt was conﬁrmed
for ASCT on an updated analysis [26,30]. The Nordic Lym-
phoma Group published the largest prospective multicenter
trial of 160 patients with MCL who received inductionwith a
“maxi-CHOP” plus rituximab alternating with high-dose
cytarabine and rituximab for a total of 6 courses. Re-
sponders received HDT with BEAM or high-dose carmustine,
etoposide, cytarabine, and cyclophosphamide plus rituximab
followed by ASCT. The 6-year PFS and OS were 66% and 70%,
respectively, with no relapses occurring after 5 years [13].
These results were further supported by the CALGB 59909,
in which 77 patients received augmented R-CHOP and
methotrexate induction followed by HDT, with etoposide-
cytarabine-rituximab, and ASCT resulting in comparable
5-year PFS and OS of 56% and 64%, respectively [14]. These
data demonstrates that, in the modern era of rituximab-
based induction and intensiﬁed chemotherapy/ASCT, about
60% of patients with MCL can be cured, yet the sobering fact
remains that 30% to 40% of patients still eventually relapse
after ASCT, and new consolidation therapies are required to
improve the outcomes of these patients.
The CUP trial was conducted in the prerituximab era and
randomized patients with FL in ﬁrst relapse after salvage
chemotherapy to either standard chemotherapy, HDT fol-
lowed by ASCT, and HDT followed by ASCT with ex vivo
purging of the graft. The trial closed early secondary to poor
accrual and only 70 patients were evaluable. HDT followed
by ASCT signiﬁcantly improved PFS at 2 years compared with
standard chemotherapy (26% versus 58%) and graft purging
did not improve outcomes [1]. A recent single-institution
retrospective analysis has proven that the beneﬁt of HDT
and ASCT in ﬁrst relapse of FL is sustained in patients who
received rituximab with induction therapy [31]. Despite the
long duration of remission after ASCT for FL and other
indolent lymphomas, disease progression is inevitable, and
novel therapies are also required to improve the depth of
remission in these patients.
Bortezomib has demonstrated single-agent activity in
relapsed/refractory indolent NHL and MCL [23-25],
including an ORR of 33% in the PINNACLE landmark trial
[26]. In our MCL subjects, we observed a median PFS of 57%
and OS of 72% at 5 years, which is comparable to what was
observed in the Nordic Lymphoma Group and CALGB 59909
trials, suggesting that incorporation of bortezomib to stan-
dard BEAM conditioning did not result in a dramatic
improvement in outcomes. Also, we performed an explor-
atory analysis comparing our MCL study cohort to an historic
cohort of patients with MCL treated at our institution with
standard BEAM conditioning, and outcomes were essentially
identical. Demonstrating a beneﬁt for adding bortezomib to
standard BEAM regimen would require a randomized
controlled trial. It is possible that bortezomibwould bemore
efﬁcacious as a maintenance regimen after ASCT, and the
CALGB 50403 is in progress to answer this question
(NCT00310037). It is also possible that bortezomib would
have a role in induction chemotherapy, in addition to
R-CHOP (ECOG- E1405), R-EPOCH, or R-HyperCVAD. Studies
are in progress to answer these questions (NCT00433537,
NCT00114738 and NCT00477412, respectively).
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ageable, and similar to that in relapsed/refractory multiple
myeloma [32]. The incidences of peripheral neuropathy, of all
grades and of grades  3, were higher than what were
observed in the landmark myeloma APEX trial [32], but they
were comparable towhat was observed in the PINNACLE trial
of relapsed/refractory MCL patients [26]. The higher inci-
dence of peripheral neuropathy in our patients, compared
with myeloma patients treated in the APEX trial, is readily
explainable by greater exposure to neurotoxic chemothera-
peutic agents in induction. Grade 3 ileus was observed in 9%
of treated patients with 1 case of perforated jejunum, which
is higher than what was reported in the PINNACLE and APEX
trials. We also observed a higher rate of autonomic
dysfunction, manifesting as vasovagal syncope and ortho-
static hypotension. We postulate that the higher risk of
autonomic dysfunction, which also likely contributed to
ileus, is related to the confounding effect of mucositis
induced by the standard BEAM conditioning regimen,
resulting in ﬂuid loss through the gastrointestinal tract and
making the study patients more vulnerable to bortezomib-
induced autonomic neuropathy.
In conclusion, the addition of bortezomib to standard
BEAM conditioning is feasible. The toxicities were manage-
able and we did not observe any treatment-related mortal-
ities. However, we did observe an excess of autonomic
dysfunction and ileus, which is concerning for overlapping
toxicity with BEAM conditioning. Out study was not
designed to demonstrate an additional beneﬁt of adding
bortezomib to BEAM conditioning; however, we did not
observe a dramatic beneﬁt of such combination over his-
torical controls from our institution or from the published
literature. The demonstration of a beneﬁt for adding borte-
zomib to standard BEAM regimen would require a random-
ized controlled trial. However, the lack of a hint of a beneﬁt
and higher than usual toxicities observed in our study would
generate less enthusiasm for developing a phase III clinical
trial to answer that question, especially with many effective
targeted agents in the pipeline.ACKNOWLEDGMENTS
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